as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹59.1
Change
+0.03 (0.05%)
Open
₹59.11
Prev. Close
₹59.07
Day High
₹60.98
Day Low
₹58.3
Volume Analysis
Traded
125,298
Delivered
31,652
Delivery %
25.26%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •Low return on equity (8.39%)
- •Below-average fundamentals quality score (48/100)
- •Low operating margin (-1.0%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹63.3 | ₹62.14 | ₹60.62 | ₹59.46 | ₹57.94 | ₹56.78 | ₹55.26 |
| Fibonacci | ₹62.14 | ₹61.12 | ₹60.48 | ₹59.46 | ₹58.44 | ₹57.8 | ₹56.78 |
| Camarilla | ₹59.84 | ₹59.59 | ₹59.35 | ₹59.46 | ₹58.85 | ₹58.61 | ₹58.36 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-25.04%
1 Week
-0.87%
1 Month
-7.32%
3 Months
-12.51%
6 Months
+17.71%
1 Year
-34.65%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹119.15
Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
2.06%
Net margin 3.6% × asset turnover 0.44x × equity multiplier 1.3x
Company Overview
Sector
Healthcare
Market Cap
₹124 Cr
P/E (TTM)
30.6
ROE
8.39%
Book Value
₹88.5
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Alpa Laboratories Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 48/100. The strongest factor is Financial Strength (100/100), while Liquidity (6/100) is the weakest area to weigh before deciding. Notably: Low return on equity (8.39%); below-average fundamentals quality score (48/100).
TopFund Score — Fundamentals Quality
48/100 — WeakData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Stock is trading at 0.67 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −The company has delivered a poor sales growth of 1.69% over past five years.
- −Company has a low return on equity of 10.7% over last 3 years.
- −Earnings include an other income of Rs.9.58 Cr.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Alpa Laboratories appoints Ms. Diksha Jaswani as Company Secretary-cum-Compliance Officer effective 17 September 2026.
Radhika Biyani appointed Additional Independent Director from 5 Sept 2026; board committees reconstituted.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 25 | 32 | 27 | 24 | 21 | 25 | 26 | 40 | 19 | 26 | 29 | 31 | 24 |
| Expenses + | 27 | 29 | 25 | 20 | 21 | 22 | 25 | 40 | 19 | 29 | 28 | 28 | 28 |
| Operating Profit | -1 | 3 | 2 | 4 | 1 | 3 | 1 | 0 | 0 | -2 | 2 | 4 | -4 |
| OPM % | -4.48% | 10.34% | 8.9% | 14.87% | 2.47% | 13.31% | 2.83% | 0.5% | 2.25% | -8.57% | 5.2% | 11.46% | -16.55% |
| Other Income + | 4 | 3 | 4 | 4 | 5 | 7 | 9 | 2 | 12 | 3 | 1 | 0 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| Profit before tax | 3 | 6 | 5 | 7 | 5 | 10 | 9 | 2 | 12 | 0 | 2 | 3 | 1 |
| Tax % | 0.0% | 0.0% | 14.91% | 46.71% | 0.0% | 20.31% | 0.0% | 201.92% | 0.0% | 0.0% | 9.2% | 55.05% | 0.0% |
| Net Profit + | 3 | 6 | 5 | 4 | 5 | 8 | 9 | -2 | 12 | 0 | 2 | 1 | 1 |
| EPS in Rs | 1 | 3 | 2 | 2 | 2 | 4 | 4 | -1 | 6 | 0 | 1 | 1 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 57 | 53 | 63 | 62 | 77 | 85 | 97 | 112 | 93 | 109 | 110 | 106 | 111 |
| Expenses + | 54 | 47 | 56 | 58 | 76 | 80 | 90 | 101 | 85 | 100 | 105 | 103 | 112 |
| Operating Profit | 3 | 7 | 7 | 4 | 1 | 6 | 8 | 11 | 8 | 9 | 5 | 3 | -1 |
| OPM % | 6.0% | 13.0% | 11.0% | 7.0% | 1.5% | 7.0% | 8.0% | 10.0% | 9.0% | 8.0% | 4.4% | 3.1% | -1.0% |
| Other Income + | 2 | 5 | 3 | 5 | 5 | 0 | 4 | 11 | 9 | 14 | 23 | 16 | 10 |
| Interest | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 1 | 3 | 3 | 3 | 3 | 1 | 2 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | -3 | 10 | 6 | 5 | 3 | 3 | 11 | 20 | 16 | 21 | 26 | 17 | 6 |
| Tax % | -48.0% | 30.0% | 55.0% | 39.0% | 63.0% | 36.0% | 33.0% | 28.0% | 21.0% | 19.0% | 24.0% | 10.0% | — |
| Net Profit + | -1 | 7 | 3 | 3 | 1 | 2 | 7 | 14 | 13 | 17 | 20 | 15 | 4 |
| EPS in Rs | -1 | 3 | 1 | 1 | 0 | 1 | 3 | 7 | 6 | 8 | 9 | 7 | 2 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 66 | 72 | 74 | 77 | 77 | 79 | 87 | 101 | 114 | 131 | 150 | 165 |
| Borrowings + | 29 | 24 | 11 | 6 | 2 | 0 | 0 | 6 | 2 | 5 | 0 | 3 |
| Other Liabilities + | 13 | 27 | 20 | 18 | 21 | 21 | 33 | 28 | 30 | 25 | 51 | 53 |
| Total Liabilities | 128 | 144 | 126 | 122 | 121 | 121 | 140 | 155 | 167 | 182 | 223 | 242 |
| Fixed Assets + | 5 | 15 | 15 | 10 | 8 | 6 | 7 | 9 | 7 | 11 | 21 | 20 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Investments | 10 | 12 | 13 | 31 | 49 | 57 | 51 | 75 | 78 | 98 | 118 | 142 |
| Other Assets + | 113 | 118 | 97 | 81 | 65 | 58 | 81 | 71 | 82 | 73 | 84 | 80 |
| Total Assets | 128 | 144 | 126 | 122 | 121 | 121 | 140 | 155 | 167 | 182 | 223 | 242 |
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -2 | -22 | 17 | -13 | -1 | 18 | -2 | 10 | 9 | 4 | 18 | 10 |
| Cash from Investing Activity + | 37 | -8 | -2 | -11 | -15 | -11 | 6 | -16 | 2 | -13 | -12 | -12 |
| Cash from Financing Activity + | 7 | -6 | -15 | 9 | -5 | -1 | 0 | 5 | -4 | 3 | -5 | 2 |
| Net Cash Flow | 42 | -36 | 0 | -15 | -20 | 5 | 4 | 0 | 7 | -7 | 1 | 1 |
| CFO/OP | -92 | -277 | 283 | -263 | 102 | 324 | 15 | 123 | 155 | 85 | 466 | 389 |
| Free Cash Flow | -3 | -32 | 16 | -15 | -2 | 15 | -5 | 8 | 8 | -3 | 7 | 6 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 42.59% | 41.74% | 42.21% | 42.35% | 41.97% | 42.34% | 42.3% | 42.34% | 42.36% | 42.35% | 42.43% | 42.38% |
| Promoters | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.19% | 57.19% |
| FII | 0.11% | 0.95% | 0.5% | 0.36% | 0.74% | 0.35% | 0.4% | 0.36% | 0.35% | 0.36% | 0.38% | 0.35% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.07% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Alpa Laboratories Ltd (this stock) | 124 | 30.6 | 0.67 | 8.39% |
| Balaxi Pharma Ltd | 126 | 52.0 | 0.51 | 0.59% |
| Vaishali Pharma Limited | 112 | 25.2 | 1.63 | 6.02% |
| Makers Laboratories Ltd. | 107 | 31.4 | 1.48 | 3.17% |
| Parnax Lab Ltd. | 149 | 14.8 | 1.56 | 14.4% |
| Sunil Healthcare Ltd. | 78 | 21.1 | 1.12 | 6.01% |
| Bal Pharma Ltd. | 175 | 24.4 | 2.13 | 7.87% |
Which Mutual Funds Hold Alpa Laboratories Ltd?
Frequently Asked Questions about Alpa Laboratories Ltd
Alpa Laboratories Ltd (ALPA) closed at ₹59.1 on NSE on 25 September 2026, up 0.03 (0.05%) from the previous close.
Alpa Laboratories Ltd trades on the NSE (National Stock Exchange of India) under the symbol ALPA.
Alpa Laboratories Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 30.6.
Alpa Laboratories Ltd has a dividend yield of 0.0%.
Alpa Laboratories Ltd's 52-week high is ₹99.8 and its 52-week low is ₹46.0.
Alpa Laboratories Ltd has a market capitalisation of ₹124 crore.
Alpa Laboratories Ltd has a TopFund Quality Score of 48/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Alpa Laboratories Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.